Kimmel P L, Phillips T M, Simmens S J, Peterson R A, Weihs K L, Alleyne S, Cruz I, Yanovski J A, Veis J H
Department of Medicine, George Washington University Medical Center, Washington, D.C., USA.
Kidney Int. 1998 Jul;54(1):236-44. doi: 10.1046/j.1523-1755.1998.00981.x.
Although the medical determinants of mortality in patients with end-stage renal disease (ESRD) treated with hemodialysis (HD) are well appreciated, the contribution of immunologic parameters to survival in such patients is unclear, especially when variations in age, medical comorbidity and nutrition are controlled. In addition, although dysregulation of cytokine metabolism has been appreciated in patients with ESRD, the association of these parameters with outcomes has not been established. Recently, the type of dialyzer used in patients' treatment has been associated with survival, but the mechanisms underlying these findings, including their immune effects, have not been established. We conducted a prospective, cross-sectional, observational multicenter study of urban HD patients to determine the contribution of immunological factors to patient survival. We hypothesized increased proinflammatory cytokines would be associated with increased mortality, and that improved immune function would be associated with survival.
Patients were assessed using demographic and anthropometric indices, Kt/V, protein catabolic rate (PCR) and immunologic variables including circulating cytokine [interleukin (IL)-1, IL-2, IL-4, IL-5, IL-6, IL-12, IL-13 and tumor necrosis factor (TNF)-alpha] levels, total hemolytic complement activity (CH50), and T cell number and function. A severity index, previously demonstrated to be a mortality marker, was used to grade medical comorbidity. A Cox proportional hazards model, controlling for patients' age, severity index, level of serum albumin concentration, dialyzer type and dialysis site was used to asses relative survival risk.
Two hundred and thirty patients entered the study. The mean (+/- SD) age of the population was 54.4 +/- 14.2 years, mean serum albumin concentration was 3.86 +/- 0.47 g/dl, mean PCR was 1.1 +/- 0.28 g/kg/day, and mean Kt/V 1.2 +/- 0.3. Patients' serum albumin concentration was correlated with levels of Kt/V and PCR, and their circulating IL-13 and TNF-alpha levels, but negatively with their circulating IL-2 levels, T-cell number and T-cell antigen recall function. T-cell antigen recall function correlated negatively with PCR, but not Kt/V. There was no correlation of any other immune parameter and medical or demographic factor. Immune parameters, were all highly intercorrelated. Mean level of circulating cytokines in HD patients were in all cases greater than those of a normal control group. There were few differences in medical risk factors or immune parameters between patients treated with different types of dialyzers. After an almost three-year mean follow-up period, increased IL-1, TNF-alpha, IL-6, and IL-13 levels were significantly associated with increased relative mortality risk, while higher levels of IL-2, IL-4, IL-5, IL-12, T-cell number and function, and CH50 were associated with improved survival. The difference in survival between patients treated with unmodified cellulose dialyzers and modified or synthetic dialyzers approached the level of statistical significance, but there were no differences in levels of circulating cytokines between these two groups.
Higher levels of circulating proinflammatory cytokines are associated with mortality, while immune parameters reflecting improved T-cell function are associated with survival in ESRD patients treated with HD, independent of other medical risk factors. These factors may serve as markers for outcome. The mechanism underlying the relationship of immune function and survival, and the effect of interventions to normalize immune function in HD patients should be studied.
尽管接受血液透析(HD)治疗的终末期肾病(ESRD)患者死亡率的医学决定因素已得到充分认识,但免疫参数对这类患者生存的贡献尚不清楚,尤其是在年龄、合并症和营养状况差异得到控制的情况下。此外,尽管已认识到ESRD患者存在细胞因子代谢失调,但这些参数与预后的关联尚未确立。最近,患者治疗中使用的透析器类型与生存相关,但这些发现的潜在机制,包括其免疫效应,尚未明确。我们对城市HD患者进行了一项前瞻性、横断面、观察性多中心研究,以确定免疫因素对患者生存的贡献。我们假设促炎细胞因子增加与死亡率增加相关,而免疫功能改善与生存相关。
使用人口统计学和人体测量指标、Kt/V、蛋白质分解代谢率(PCR)以及免疫变量对患者进行评估,免疫变量包括循环细胞因子[白细胞介素(IL)-1、IL-2、IL-4、IL-5、IL-6、IL-12、IL-13和肿瘤坏死因子(TNF)-α]水平、总溶血补体活性(CH50)以及T细胞数量和功能。使用先前已证明为死亡率标志物的严重程度指数对合并症进行分级。使用Cox比例风险模型,控制患者的年龄、严重程度指数、血清白蛋白浓度水平、透析器类型和透析部位,以评估相对生存风险。
230名患者进入研究。总体人群的平均(±标准差)年龄为54.4±14.2岁,平均血清白蛋白浓度为3.86±0.47 g/dl,平均PCR为1.1±0.28 g/kg/天,平均Kt/V为1.2±0.3。患者的血清白蛋白浓度与Kt/V和PCR水平、循环IL-13和TNF-α水平相关,但与循环IL-2水平、T细胞数量和T细胞抗原回忆功能呈负相关。T细胞抗原回忆功能与PCR呈负相关,但与Kt/V无关。其他免疫参数与医学或人口统计学因素均无相关性。免疫参数之间均高度相关。HD患者循环细胞因子的平均水平在所有情况下均高于正常对照组。不同类型透析器治疗的患者在医学风险因素或免疫参数方面几乎没有差异。经过近三年的平均随访期,IL-1、TNF-α、IL-6和IL-13水平升高与相对死亡风险增加显著相关,而IL-2、IL-4、IL-5、IL-12、T细胞数量和功能以及CH50水平较高与生存改善相关。使用未改性纤维素透析器与改性或合成透析器治疗的患者生存差异接近统计学意义水平,但两组之间循环细胞因子水平无差异。
循环促炎细胞因子水平较高与死亡率相关,而反映T细胞功能改善的免疫参数与接受HD治疗的ESRD患者的生存相关,独立于其他医学风险因素。这些因素可能作为预后标志物。应研究免疫功能与生存关系的潜在机制以及HD患者免疫功能正常化干预措施的效果。